MediPharm Labs Corp.
MEDIF
$0.0573
$0.00183.24%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.88M | 30.60M | 28.71M | 27.86M | 27.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.88M | 30.60M | 28.71M | 27.86M | 27.43M |
| Cost of Revenue | 20.26M | 20.73M | 18.19M | 16.46M | 18.01M |
| Gross Profit | 10.62M | 9.87M | 10.51M | 11.40M | 9.43M |
| SG&A Expenses | 14.65M | 16.13M | 15.40M | 16.06M | 17.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -25.40K | -47.70K | 83.40K | -99.70K | 22.20K |
| Total Operating Expenses | 35.12M | 37.04M | 33.96M | 32.66M | 36.01M |
| Operating Income | -4.24M | -6.44M | -5.25M | -4.80M | -8.58M |
| Income Before Tax | -5.42M | -7.83M | -8.85M | -10.04M | -10.30M |
| Income Tax Expenses | -- | -- | -200.70K | -202.90K | -202.90K |
| Earnings from Continuing Operations | -5.42 | -7.83 | -8.65 | -9.84 | -10.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.42M | -7.83M | -8.65M | -9.84M | -10.10M |
| EBIT | -4.24M | -6.44M | -5.25M | -4.80M | -8.58M |
| EBITDA | -2.66M | -4.56M | -3.32M | -2.78M | -6.57M |
| EPS Basic | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.64B | 1.63B | 1.60B | 1.58B | 1.57B |
| Average Diluted Shares Outstanding | 1.64B | 1.63B | 1.60B | 1.58B | 1.57B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |